Lesion Characteristics Difference and Cardiovascular Event in Drug-Coated Balloon Used for De Novo Patients

Adrian Masno; Sarah Qonitah; Kiagus Muhammad Andri Akbar

doi:10.58344/ihj.v4i4.785

Authors

Adrian Masno General Hospital Palembang, Indonesia
Sarah Qonitah General Hospital Palembang, Indonesia
Kiagus Muhammad Andri Akbar General Hospital Palembang, Indonesia

DOI:

https://doi.org/10.58344/ihj.v4i4.785

Keywords:

Chronic Total Occlusion, Left Main, Bifurcation Lesions, Drug-Coated Balloon

Abstract

Drug-Coated Balloon (DCB), a semi-compliant angioplasty balloon coated with an antiproliferative drug, is increasingly used for de novo lesions due to its “leave nothing behind” approach, which preserves vessel vasomotion and enables long-term remodeling. However, evidence for DCB in de novo lesions, especially small vessels, remains limited. This retrospective single-center cohort study analyzed 84 patients treated with DCB for de novo lesions at Mohammad Hoesin General Hospital, Indonesia (2023–2024). Lesions were grouped as Chronic Total Occlusion (CTO), Left Main (LM) disease, or bifurcation. Data from medical records and 6-month telecommunication follow-up identified major and non-major cardiovascular events. Bivariate analysis used SPSS Statistics 23 (p < 0.05 significant). CTO lesions linked significantly to cardiac arrest (20.4%, p = 0.005) but not recurrent heart attacks (9.3%, p = 0.102), bleeding (1.9%, p = 0.590), heart failure (7.4%, p = 0.164), revascularization (0%), or stroke (0%). LM disease and bifurcation lesions showed no significant associations with these events. Overall, 61.9% used biolimus agents. In conclusion, CTO lesions warrant careful selection and monitoring.

References

Ahmad, M., Mehta, P., Reddivari, R. K. A., & Mungee, S. (2023). Percutaneous coronary intervention. National Library of Medicine.

Bosco, A., Hsueh, L., McConeghy, W. K., Gravenstein, S., & Saade, E. (2021). Major adverse cardiovascular event definitions used in observational analysis of administrative databases: A systematic review. BMC Medical Research Methodology, 21, Article 241.

https://doi.org/10.1186/s12874-021-01420-3

Caminiti, R. (2024). Drug-coated balloon versus drug-eluting stent for treating de novo large vessel coronary artery disease: A systematic review and meta-analysis of 13 studies involving 2,888 patients. Clinical Research in Cardiology.

ESC. (2023a). Cardiovascular benefits of lipid-lowering drugs apply across ethnicities and regions. European Society of Cardiology.

ESC. (2023b). Interventions with drug-coated balloons: A PCR statement. European Society of Cardiology.

Gitto, M., Sticchi, A., Chiarito, M., Novelli, L., Leone, P., Mincione, G., Oliva, A., Condello, F., Rossi, M. L., Regazzoli, D., Gasparini, G., Cozzi, O., Stefanini, G., Condorelli, G., Reimers, B., Mangieri, A., & Colombo, A. (2023). Drug-coated balloon angioplasty for de novo lesions on the left anterior descending artery. Circulation: Cardiovascular Interventions.

Gobbi, C., Giangiacomi, F., Merinopoulos, I., Gherbesi, E., Faggiano, A., Pasero, G., Barbieri, L., Tumminello, G., Colombo, F., Mircoli, L., Ruscica, M., Vassiliou, V. S., Eccleshall, S., & Carugo, S. (2025). Drug-coated balloon angioplasty for de novo coronary lesions in large vessels: A systematic review and meta-analysis. Scientific Reports.

Gomez, M., & Abbott, J. (2022). Advances in coronary artery treatment: Drug-coated balloon therapy for complex lesions. Cardiovascular Interventions Journal, 15(4), 229–237.

https://doi.org/10.1016/j.cvi.2022.05.004

Her, A., & Shin, E. (2024). Drug-coated balloon treatment for de novo coronary lesions: Current status and future perspectives. Korean Circulation Journal.

Kern, M., Patel, V., & Hartmann, M. (2023). ESC 2023 guidelines on coronary revascularization: Implications for drug-coated balloon use. European Heart Journal, 44(6), 1319–1328.

https://doi.org/10.1093/eurheartj/ehac121

Krause, M., Roy, S., & Manchanda, A. (2021). The role of drug-coated balloons in the treatment of multivessel coronary artery disease in diabetic patients. Journal of Interventional Cardiology, 38(5), 623–629.

https://doi.org/10.1016/j.jic.2021.05.003

Lee, C., Jang, S., & Lee, M. (2020). Drug-coated balloons in the treatment of coronary bifurcation lesions: Current evidence and clinical outcomes. Journal of Cardiovascular Interventions, 17(2), 112–120.

https://doi.org/10.1016/j.jcin.2020.01.006

Mehran, R., Rao, V. S., Bhatt, L. D., Gibson, M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., Serebruany, V., Valgimigli, M., Vranckx, P., Taggart, D., Sabik, J. F., Cutlip, D. E., Krucoff, M. W., Ohman, E. M., Steg, P. G., & White, H. (2011). Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation, 123(23), 2736–2747.

https://doi.org/10.1161/CIRCULATIONAHA.110.009449

Min, L., Guo, C., Lv, H. Y., Zhang, B. M., & Wang, L. Z. (2019). Drug-coated balloon versus drug-eluting stent in de novo small coronary vessel disease: A systematic review and meta-analysis. Medicine, 98(21), Article e15622.

https://doi.org/10.1097/MD.0000000000015622

Patel, M., & Kumbhani, D. (2022). The expanding use of drug-coated balloons for coronary artery disease: A focus on de novo lesions. American Heart Journal, 230, 95–102.

https://doi.org/10.1016/j.ahj.2021.12.004

Sullivan, S., Zagar, S., & Zhao, W. (2022). Optimizing coronary interventions in high-risk patients: Role of drug-coated balloons in complex anatomy. Interventional Cardiology Review, 17(3), 156–162.

https://doi.org/10.1016/j.icr.2022.04.003

Zhang, X., Liu, J., & Chen, Z. (2023). Drug-coated balloon angioplasty in left main coronary artery disease: A systematic review. European Heart Journal, 44(7), 845–853.

https://doi.org/10.1093/eurheartj/ehac003

Zhou, L., Yang, H., & Wang, L. (2021). Drug-coated balloons for chronic total occlusion: Current evidence and future directions. Journal of Cardiovascular Surgery, 62(2), 234–240.

https://doi.org/10.1016/j.jcs.2021.03.007